作者
VA Papadimitrakopoulou, TS Mok, J-Y Han, M-J Ahn, A Delmonte, SS Ramalingam, SW Kim, FA Shepherd, J Laskin, Y He, H Akamatsu, WSME Theelen, W-C Su, Thomas John, M Sebastian, H Mann, M Miranda, G Laus, Y Rukazenkov, Y-L Wu
发表日期
2020/11/1
期刊
Annals of Oncology
卷号
31
期号
11
页码范围
1536-1544
出版商
Elsevier
简介
Background
In AURA3 (NCT02151981), osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), significantly prolonged progression-free survival and improved response in patients with EGFR T790M advanced non-small-cell lung cancer (NSCLC) and progression on prior EGFR-TKI treatment. We report the final AURA3 overall survival (OS) analysis.
Patients and methods
Adult patients were randomized 2 : 1 to osimertinib (80 mg orally, once daily) or pemetrexed plus carboplatin/cisplatin (platinum–pemetrexed) intravenously, every 3 weeks (≤6 cycles). Patients could crossover to osimertinib on progression confirmed by blinded independent central review. OS and safety were secondary end points.
Results
A total of 279 patients were randomly assigned to receive osimertinib and 140 to platinum–pemetrexed (136 received treatment). At data cut-off (DCO; 15 March …
学术搜索中的文章
VA Papadimitrakopoulou, TS Mok, JY Han, MJ Ahn… - Annals of Oncology, 2020